Pharmaceutical Regulatory Affair

Data Monitoring in Clinical Trials: A Practical Perspective by Susan Ellenberg,

There has been substantial growth in the use of data monitoring committees in recent years, by both government agencies pharmaceutical regulatory affair and the pharmaceutical industry. This growth has been brought about by increasing recognition of the value of such committees in safeguarding trial participants as well as protecting trial integrity pharmaceutical regulatory affair and the validity of conclusions. This very timely book describes the operation of data monitoring committees, pharmaceutical regulatory affair and provides an authoritative guide to their establishment, purpose pharmaceutical regulatory affair and responsibilities.Provides a practical overview of data monitoring in clinical trials. Describes the purpose, responsibilities pharmaceutical regulatory affair and operation of data monitoring committees. Provides directly applicable advice for those managing pharmaceutical regulatory affair and conducting clinical trials, pharmaceutical regulatory affair and those serving on data monitoring committees. Gives insight into clinical data monitoring to those sitting on regulatory pharmaceutical regulatory affair and ethical committees. Discusses issues pertinent to those working in clinical trials in both the US pharmaceutical regulatory affair and Europe.The practical guidance provided by this book will be of use to professionals working in and/or managing clinical trials, in academic, government pharmaceutical regulatory affair and industry settings, particularly medical statisticians, clinicians, trial co-ordinators, pharmaceutical regulatory affair and those working in regulatory affairs pharmaceutical regulatory affair and bioethics.
CLICK HERE

Guiding Icarus: Merging Bioethics With Corporate Interests by Rahul K. Dhanda,

" There is a palpable need for business to explore the issues Dhanda raises. Guiding Icarus offers a flight plan." — from the Foreword by Philip R. Reilly Guiding ICARUS Merging Bioethics with Corporate Interests Rahul K. Dhanda While bioethicists may enjoy the most thorough appreciation of both the promise pharmaceutical regulatory affair and perils of new biotechnologies, international corporations are in fact the entities generating these technologies pharmaceutical regulatory affair and determining their application. An industry insider versed in the language of bioethics, Rahul Dhanda offers in Guiding Icarus: Merging Bioethics with Corporate Interests a Rosetta stone to these two camps, explaining why each needs the other, why their disparate concerns often cohere, pharmaceutical regulatory affair and why an ethical business is likely a successful one. The author develops a dialogue between bioethics pharmaceutical regulatory affair and corporate interests by examining case studies of several hot-button issues, including: Genetically modified foodsDNA data bankingPersonalized medicineStem cell research In each instance he provides a treatment of the particular science under consideration, a list of the benefits of the technology, a description of the ethical issues involved, an account of past industry response, pharmaceutical regulatory affair and recommendations for future action. Given the expansive nature of biotechnology, ramifications in the pharmaceutical pharmaceutical regulatory affair and agricultural industries are covered in depth as well. The book also features a Foreword by world-renowned bioethicist pharmaceutical regulatory affair and biotechnology CEO Philip R. Reilly as well as a step-by-step discussion of the components of business pharmaceutical regulatory affair and bioethical issues. Written for a general audience, Guiding Icarus will be particularly useful to biotechnologists,regulatory affairs managers, pharmaceutical regulatory affair and corporate officers of biotechnology firms, as well as bioethicists in the academic community. Dhanda’ s peerless text provides a unique tool for understanding pharmaceutical regulatory affair and addressing the ethical dilemmas confronting society in the 21st century.
CLICK HERE

List of Chinese regulatory agencies for the pharmaceutical industry - ===SFDA China===

Royal Pharmaceutical Society of Great Britain - The Royal Pharmaceutical Society of Great Britain (RPSGB) is the regulatory and professional body for pharmacists in England, Scotland and Wales. It has its headquarters at 1, Lambeth High Street, in the Borough of Lambeth in London.

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use - The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) is a project that brings together the regulatory authorities of Europe, Japan and the United States and experts from the pharmaceutical industry in the three regions to discuss scientific and technical aspects of pharmaceutical product registration.

Test data exclusivity - Test data exclusivity refers to protection of clinical test data required to be submitted to a regulatory agency to prove safety and efficacy of a new drug, and prevention of generic drug manufacturers from relying on this data in their own applications. Pharmaceutical companies argue that since test data is so expensive to produce, it is an unfair advantage to let other companies rely on that data without cost.

pharmaceuticalregulatoryaffair

Myriad Pharmaceutical - Myriad Pharmaceutical Aquarium Pharmaceuticals Ammo-Chips Ammonia Removing Resin (48 oz.) Removes ammonia--the number one killer of tropical fish. Protects against ammonia buildup or surge. Economical ammonia remover developed especially for the tropical fish myriad pharmaceutical and goldfish hobbyist. Great in all freshwater systems, including outdoor ponds myriad pharmaceutical and aquariums with undergravel filters. Keeps goldfish healthy myriad pharmaceutical and goldfish bowls clean up to two weeks. Can be recharged with Aquarium Pharmaceuticals Salt. FOR BEST PRICE Aquarium Pharmaceuticals Bio ...

Emphasizes the importance of demonstrating the stability-indicating nature of an assay?describes the drug registration process, and supplies